Moderna, Inc. financial data

Symbol
MRNA on Nasdaq
Industry
Biological Products, (No Diagnostic Substances)
Location
325 Binney Street, Cambridge, MA
State of incorporation
Delaware
Fiscal year end
December 31
Former names
Moderna Therapeutics, Inc. (to 8/24/2016)
Latest financial report
10-Q - Q2 2024 - Aug 1, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 333 % +21%
Quick Ratio 11.4 % -53.3%
Debt-to-equity 35.6 % +3.82%
Return On Equity -45.3 % -784%
Return On Assets -33.4 % -777%
Operating Margin 4.82 % -92.9%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 384M shares +1%
Common Stock, Shares, Outstanding 384M shares +0.79%
Entity Public Float 40.2B USD -17.6%
Common Stock, Value, Issued 0 USD
Weighted Average Number of Shares Outstanding, Basic 384M shares +0.79%
Weighted Average Number of Shares Outstanding, Diluted 384M shares +0.79%

Income Statement

Label TTM Value / Value Unit Change %
Revenues 10.7B USD -53.7%
Revenue from Contract with Customer, Excluding Assessed Tax 5.05B USD -29.9%
Research and Development Expense 4.85B USD +12.5%
General and Administrative Expense 1.45B USD +12.7%
Costs and Expenses 9.69B USD -4.5%
Operating Income (Loss) -4.64B USD -1004%
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest -4.33B USD -630%
Income Tax Expense (Benefit) 1.54B USD
Net Income (Loss) Attributable to Parent -5.87B USD -586%
Earnings Per Share, Basic -15.3 USD/shares -578%
Earnings Per Share, Diluted -15.3 USD/shares -633%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 2.48B USD -34.8%
Accounts Receivable, after Allowance for Credit Loss, Current 163M USD -29.7%
Inventory, Net 399M USD -44.2%
Other Assets, Current 31M USD -41.5%
Assets, Current 9.66B USD -8.85%
Deferred Income Tax Assets, Net 81M USD -94.5%
Operating Lease, Right-of-Use Asset 775M USD +496%
Goodwill 52M USD 0%
Other Assets, Noncurrent 641M USD -50.3%
Assets 15.7B USD -28.3%
Accounts Payable, Current 279M USD -10%
Employee-related Liabilities, Current 187M USD +48.4%
Accrued Liabilities, Current 1.33B USD -10.5%
Contract with Customer, Liability, Current 702M USD -32.5%
Liabilities, Current 2.36B USD -24.3%
Contract with Customer, Liability, Noncurrent 95M USD -86.3%
Operating Lease, Liability, Noncurrent 668M USD +542%
Other Liabilities, Noncurrent 266M USD +53.8%
Liabilities 3.97B USD -19.6%
Accumulated Other Comprehensive Income (Loss), Net of Tax -71M USD +73%
Retained Earnings (Accumulated Deficit) 11.2B USD -34.5%
Stockholders' Equity Attributable to Parent 11.7B USD -30.9%
Liabilities and Equity 15.7B USD -28.3%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -989M USD +19.3%
Net Cash Provided by (Used in) Financing Activities 14M USD
Net Cash Provided by (Used in) Investing Activities 118M USD -94.1%
Common Stock, Shares Authorized 1.6B shares 0%
Common Stock, Shares, Issued 384M shares +0.79%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect -857M USD -451%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 2.48B USD -35.1%
Deferred Tax Assets, Valuation Allowance 2.22B USD +1335%
Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent 0.21 pure 0%
Deferred Tax Assets, Gross 2.68B USD +96%
Operating Lease, Liability 693M USD +402%
Payments to Acquire Property, Plant, and Equipment 196M USD +73.5%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -5.68B USD -579%
Lessee, Operating Lease, Liability, to be Paid 1.16B USD +575%
Operating Lease, Liability, Current 25M USD -26.5%
Lessee, Operating Lease, Liability, to be Paid, Year Two 70M USD +250%
Lessee, Operating Lease, Liability, to be Paid, Year One 69M USD +46.8%
Operating Lease, Weighted Average Discount Rate, Percent 0.08 pure 0%
Deferred Income Tax Expense (Benefit) -146M USD -192%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 468M USD +1276%
Lessee, Operating Lease, Liability, to be Paid, Year Three 75M USD +317%
Deferred Tax Assets, Operating Loss Carryforwards 90M USD +52.5%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 162M shares 0%
Unrecognized Tax Benefits 231M USD +80.5%
Lessee, Operating Lease, Liability, to be Paid, Year Four 76M USD +300%
Additional Paid in Capital 631M USD +227%
Preferred Stock, Shares Outstanding 0 shares
Depreciation, Depletion and Amortization 524M USD +45.2%
Deferred Tax Assets, Net of Valuation Allowance 454M USD -62.5%
Share-based Payment Arrangement, Expense 369M USD +31.3%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%